Literature DB >> 9394002

Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock.

J A Wagner1, K Varga, E F Ellis, B A Rzigalinski, B R Martin, G Kunos.   

Abstract

Anandamide, an endogenous cannabinoid ligand, binds to CB1 cannabinoid receptors in the brain and mimics the neurobehavioural actions of marijuana. Cannabinoids and anandamide also elicit hypotension mediated by peripheral CB1 receptors. Here we report that a selective CB1 receptor antagonist, SR141716A, elicits an increase in blood pressure in rats subjected to haemorrhagic shock, whereas similar treatment of normotensive rats or intracerebroventricular administration of the antagonist during shock do not affect blood pressure. Blood from haemorrhaged rats causes hypotension in normal rats, which can be prevented by SR141716A but not by inhibition of nitric oxide synthase in the recipient. Macrophages and platelets from haemorrhaged rats elicit CB1 receptor-mediated hypotension in normotensive recipients, and incorporate arachidonic acid or ethanolamine into a product that co-elutes with anandamide on reverse-phase high-performance liquid chromatography. Also, macrophages from control rats stimulated with ionomycin or bacterial phospholipase D produce anandamide, as identified by gas chromatography and mass spectrometry. These findings indicate that activation of peripheral CB1 cannabinoid receptors contributes to haemorrhagic hypotension, and anandamide produced by macrophages may be a mediator of this effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9394002     DOI: 10.1038/37371

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  64 in total

1.  Functional CB1 cannabinoid receptors in human vascular endothelial cells.

Authors:  J Liu; B Gao; F Mirshahi; A J Sanyal; A D Khanolkar; A Makriyannis; G Kunos
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

Review 2.  The complexities of the cardiovascular actions of cannabinoids.

Authors:  Michael D Randall; David A Kendall; Saoirse O'Sullivan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

3.  Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats.

Authors:  Grzegorz Godlewski; Barbara Malinowska; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

4.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

Review 5.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

Review 6.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

7.  Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine.

Authors:  Yuji Kadoi; Fumio Goto
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

Review 8.  Meet Your Stress Management Professionals: The Endocannabinoids.

Authors:  Terri A deRoon-Cassini; Todd M Stollenwerk; Margaret Beatka; Cecilia J Hillard
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

Review 9.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

Review 10.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.